

O que um paciente diabético precisa para manter seu controle glicêmico em equilíbrio? ⁷



Tratamento medicamentoso adequado: insulina/hipoglicemiantes orais

Cuidados nutricionais de acordo com as recomendações

Atividade física

Diben®

A dieta enteral da Fresenius Kabi para pacientes diabéticos e com hiperglicemia!

Tabela Nutricional

Por 100ml	
Dens. calórica (Kcal/ml)	1,0
Proteína (% / g)	18,6% / 4,65g
CHO (% / g)	40% / 9,25g
Lipídio (% / g)	41,4% / 4,6g
Fibras (g / Solúsol.)	1,5g / 74,26
Fontes de proteína	Caseinato (92%) e Proteína do Soro do Leite (8%)
Fontes de CHO	Maltodextrina (41%), Amido de Tapioca (34%) e Frutose (25%)
Fontes de Fibras	Fibra de Tapioca (76%) e Celulose Microcristalina (24%)
Relação Fibra Solúsol	74,26
Fontes de Lipídio	Óleo de Girassol de alto teor oleico (54%), Óleo de Canola (43%) e Óleo de Peixe (3%)
Relação ω6:ω3	3:1
Minerais	
Sódio (mg)	85
Potássio (mg)	143
Cloreto (mg)	124
Cálcio (mg)	80
Fósforo (mg)	61
Magnésio (mg)	22,5
Ferro (mg)	1,48
Zinco (mg)	1,33
Cobre (µg)	148
Manganês (mg)	0,3
Iodo (µg)	14,8
Flúor (mg)	0,15
Cromo (µg)	13
Molibdênio (µg)	11,1
Selênio (µg)	7,4
Vitaminas	
A (µg RE)	78
β caroteno (µg)	300
D (µg)	1,48
E (mg TE)	3
K (µg)	7,4
B1 (mg)	0,15
B2 (mg)	0,19
Niacina (mg)	1,8
B6 (mg)	0,18
B12 (µg)	0,3
Ác. Pantotênico (mg)	0,52
Biotina (µg)	5,6
Ác. Fólico (µg)	29,6
C (mg)	15
Colina (mg)	40,7
Osmolaridade (mosmol/l)	345
Apresentação	
EasyBag	1000ml



FRESENIUS KABI
caring for life

Diben® Diabetes? Nós cuidamos!

Referências

- Ogurtsova K et al. IDF Diabetes Atlas. Global estimates for the prevalence of Diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128(2017):40-50
- Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates for the prevalence of Diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94(3):31-21
- Jiang HJ, Stryer D, Friedman B, Andrews R. Multiple Hospitalization for patients with Diabetes. Diabetes Care. 2003; 26(5): 1421-25
- Corsino L, Dhathary K, Umptierre G. Management of Diabetes and hyperglycemia in hospitalized patients. (Updated 2014 Oct 4). In: De Groot LJ, Chrousos G, Dungan K, et al, editors Endotext (Internet) South Dartmouth (MA): MDText.com, Inc; 2000 - Available from: http://www.ncbi.nlm.nih.gov/books/NBK279093/
- Umptierre GE, et al. Hyperglycemia: an independent marker of in hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87(3): 978-82
- Danaei G et al. National, regional and global trends in fasting plasma glucose and Diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2,7 million participants. Lancet 2011; 378 (9785):31-40
- American Diabetes Association. Position Statement: Standards of Medical Care in Diabetes - 2017. Diabetes Care 2017; 40 (suppl 1): S1-S138
- Brouns F et al. Glycemic Index Methodology. Nutr Res Review 2005; 18(1): 145-71
- Du H et al. Glycemic index load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am J Clin Nutr 2008; 87(3): 655-61
- Venn BJ and Green TJ. Glycemic index and glycemic load: measurement issues and their effects on diet-disease relationships. Eur J Clin Nutr 2007; 61(1): S122-31
- Wright J. Effect of high-carbohydrate versus high-monounsaturated fatty acid diet on metabolic control in diabetes and hyperglycemic patients. Clin Nutr 1998; 17(2): 35-45
- Pohl M et al. Glycemic control in patients with type 2 Diabetes Mellitus with a disease specific enteral formula: Stage II of a randomized, controlled multicenter trial. JPEN 2009; 33 (1): 37-49
- Ela M. Enteral Nutritional support and use of diabetes-specific formulas for patients with Diabetes. Diabetes Care 2005; 28(9): 2267-79
- Olttramani K, Marques ACR, Bazotte RB, Moraes FF. Braz J of Food Res 2015; 6(3): 32-41
- Basso C, Silva LP, Bender ABB, Silveira F. Elevação dos níveis de amido resistente: efeito sobre a glicemia e na aceitabilidade do alimento. Rev Inst Adolfo Lutz. 2011; 70 (3): 276-82

FRESENIUS KABI
caring for life

Fresenius Kabi Brasil Ltda.
CNPJ: 49.324.221/0001-04
Av. Marginal Projetada, 1652
CEP: 06460-200 • Tamboré • Barueri, SP
Tel.: 11 2504.1400 • SAC: 0800 707 3855
www.fresenius-kabi.com.br



DIB001V01out17

